Key Highlights

● DiaMedica Therapeutics shares moved up about 13.00% on October 28, 2026.

● No same-day announcement accompanied the gain.

● The move stood apart from the broader market's modest session gain.

● The stock closed at $9.82 on October 28, 2026.

DiaMedica Therapeutics (NASDAQ:DMAC), a clinical-stage biotechnology company developing treatments for stroke and pregnancy-related disorders, rose sharply on Wednesday. The shares closed at $9.82, up 13.00%. A check of the company's press releases and news feeds found no announcement dated October 27 or October 28, so there is no company-specific catalyst that can be tied directly to the day's move. The gain instead appears to reflect a combination of sector-wide strength and trading interest in a small-cap stock with several clinical milestones ahead.

Company Context

The most recent company news came the week before. On October 22, DiaMedica said it had enrolled the 200th patient in ReMEDy2, its Phase 2/3 trial of DM199 in acute ischemic stroke. That milestone matters because an independent data safety monitoring board is scheduled to review the data once the first 200 patients have completed 90 days of follow-up. The company has said final enrollment could range from 300 to 728 patients depending on that review, with an analysis expected in the first quarter of 2027. The shares slipped 0.69% on the day of that announcement, suggesting it was not the immediate source of Wednesday's gain.

Session Backdrop

Days earlier, on October 19, DiaMedica moved a key opinion leader webinar on DM199 for fetal growth restriction from October 23 to November 24, 2026. The company said the change would allow it to include preliminary results from the second dosing cohort of its Phase 2 trial. It had earlier reported that the first cohort, at 5 micrograms per kilogram, was complete and that dosing in the second cohort, at 10 micrograms per kilogram, had begun. Investors who are positioning ahead of that webinar may be contributing to interest in the stock, although that cannot be confirmed from the available information.

DiaMedica's lead candidate, DM199, is a recombinant form of a human protein known as KLK1, which plays a role in regulating blood flow. The company is developing it for acute ischemic stroke and for preeclampsia and fetal growth restriction, conditions with significant unmet medical need. At its second-quarter update in August, DiaMedica reported cash and short-term investments of $43.5 million as of June 30 and said it expected that to fund operations through 2027. It also reported a quarterly net loss of $10.1 million and highlighted significant blood pressure reductions observed in its preeclampsia study.

On the regulatory front, the company said in June that it had received written feedback from the US Food and Drug Administration on the nonclinical data needed to advance DM199 in preeclampsia, and that it planned an additional rat study to support a US investigational new drug application.

The move came during a session in which biotechnology shares moved heavily on trial and financing news, with several small-cap drug developers among the market's biggest gainers. The broader indexes were quieter: the S&P 500 rose 0.3% to a record close and the Russell 2000 gained 0.4%. The Federal Reserve held its benchmark rate at 3.75% to 4.00%, and the 10-year Treasury yield hovered near 5%. A high-yield environment tends to raise the bar for cash-consuming development-stage companies, so rallies in the group often reflect shifts in risk appetite as much as company fundamentals.

What This Move Means for DiaMedica Therapeutics

Investors following DiaMedica are likely to watch the independent safety board's review of the ReMEDy2 data, the rescheduled fetal growth restriction webinar with second-cohort results, progress toward a US application in preclinical preeclampsia work, and the company's cash position in its next quarterly report. Without a disclosed catalyst, Wednesday's gain appears best explained by broader biotech strength and trading interest rather than new information from the company.